Monday, June 15, 2026

Zuckerberg’s Summit with South Korean President on the Horizon

Mark Zuckerberg, CEO of Meta, looks stoic as he listens to lawmakers question him about social media sexual exploitation during a Senate Judiciary Committee hearing on Capitol Hill in Washington, D.C., Jan. 31, 2018. 2024.1.31...

BlackRock Acquires 5.01% Stake in HLB: What This Means for Investors

BlackRock acquires a 5.01% stake in HLB, becoming the second-largest shareholder, signaling confidence in HLB's liver cancer drug.

Researchers Discover Aging Pathway Driven by Double-Stranded RNA Buildup Inside Cells

Researchers identify that accumulated double-stranded RNA (dsRNA) in cells is a key factor in aging.

How AI is Changing the Game for Drug Makers!

TechHow AI is Changing the Game for Drug Makers!
News1

The Ministry of Science and ICT and the Ministry of Health and Welfare of South Korea announced today that 26 projects have been selected for the Federated Learning-Based New Drug Development Acceleration Project and officially launched the initiative.

Federated learning is a decentralized method that enables institutions to analyze data without sharing it directly. Institutions perform internal analyses and send only the results to a central server, ensuring data privacy while still benefiting from the analysis.

This joint initiative aims to reduce the costs and time associated with new drug development using AI models based on federated learning.

Since its inception in April, the project team has chosen 26 specific tasks in three areas through a competitive application process: Federated Learning Platform Construction, Utilization and Quality Management of New Drug Development Data, and AI Solution Development.

The Ministry of Science and ICT and the Ministry of Health and Welfare will fund the research projects with a $26 million budget over five years, extending to 2028.

Kwon Hyun Jun, Director of Basic Research Policy at the Ministry of Science and ICT, expressed optimism about the project. He said, “We anticipate that the high-quality new drug development data accumulated by various institutions will be safely utilized, leading to the development of robust AI-based drug development platforms and solutions.”

Go Hyung Woo, Director of Advanced Medical Support at the Ministry of Health and Welfare, added, “We will actively support AI and data R&D to drive innovations in future healthcare and pharmaceuticals while contributing to improving public health.”

Check Out Our Content

Check Out Other Tags:

Most Popular Articles